Reversal of Ventricular Remodeling with Toprol-XL

Study identifier:276

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

-

Medical condition

Heart Failure, Congestive

Phase

Phase 3

Healthy volunteers

No

Study drug

Seloken ZOK/Toprol-XL, Placebo

Sex

All

Actual Enrollment

300

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2001
Primary Completion Date: 01 Sept 2003
Study Completion Date: 01 Sept 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: None
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2010 by AstraZeneca L.P.

Sponsors

AstraZeneca L.P.

Collaborators

-

Inclusion and exclusion criteria